Clinical Education
The Vascular Component of Melasma
Melasma is not purely an epidermal pigment disorder. Histologic research has documented increased number and size of dermal blood vessels and increased VEGF expression in melasma lesions, supporting a broader treatment-planning view.
Key facts
Published studies report that 1064 nm picosecond laser can improve melasma, though results vary and may be comparable to established treatments; outcomes depend on individual factors and a course of treatment.
Melasma is not only what you can see on the surface
The visible problem is brown pigment. The biology underneath it is more complicated.
One of the most important findings in melasma research is that lesional skin can show increased dermal vascularity. In a histologic study of 50 women with melasma, researchers found a significantly greater number and size of blood vessels in melasma lesions compared with adjacent normal skin, together with increased VEGF expression. View the PubMed record.
That changes the conversation.
It means melasma should not automatically be reduced to:
brown pigment → pigment laser → done.
What the vascular evidence does — and does not — prove
The evidence supports a broader understanding of melasma biology.
It does not prove that every patient needs vascular-directed laser treatment. It does not prove that every visible vessel is driving the condition. And it does not justify treating melasma aggressively with heat.
What it does support is a more sophisticated treatment question:
If melasma can involve both pigmentary and vascular changes, should the platform give the provider more than one treatment behavior?
That is a much better technology question than asking whether a device has a generic “melasma mode.”
The 2025 combined-1064 study is worth paying attention to
A randomized evaluator-blinded 2025 study compared a 755 nm picosecond alexandrite protocol with a combined Q-switched plus long-pulse 1064 nm Nd:YAG strategy in 40 patients with Fitzpatrick III–IV skin.
Both groups improved. The combined 1064 nm group achieved significantly greater MASI improvement overall. View the PubMed record.
That study does not isolate the mechanism of benefit, so we should not claim it proves the long-pulse component improved melasma by treating vascularity.
But the result is commercially and clinically important for another reason:
A multi-mode 1064 nm strategy outperformed a single 755 nm picosecond strategy in that trial.
That reinforces the idea that melasma treatment should be evaluated by wavelength and treatment architecture, not by pulse-duration branding alone.
Why this matters for Pro 1 Pico
Pro 1 Pico provides two distinct 1064 nm treatment behaviors relevant to this discussion:
Picosecond 1064 nm
A photoacoustic pigment-focused pathway.
Long-pulse 1064 nm
A separate photothermal pathway for appropriate vascular and thermal targets.
They are not the same mode, and they should not be presented as interchangeable.
That distinction is the strength.
A provider has the ability to work from a 1064 nm-first platform while selecting the energy-delivery behavior that fits the treatment objective rather than forcing every patient into one interaction.
More complete technology. More complete treatment planning.
Melasma remains a managed, recurrence-prone condition. No single mechanism explains every case and no device should be marketed as if one setting permanently solves it.
But the vascular literature gives us a valuable reason to reject the simplistic idea that melasma is just superficial pigment.
And that gives Pro 1 Pico a clear, defensible position:
1064 nm for pigment-focused picosecond treatment, plus a separate long-pulse 1064 nm pathway when appropriate — within one broader multi-mode platform.
Continue reading
- Melasma Treatment: Why Wavelength and Treatment Strategy Matter
- Melasma in Darker Skin: Why 1064 nm Matters
- Pro 1 Pico for Melasma
Treatment selection and parameters remain provider-directed. Results vary, and melasma may recur.
Technologies covered
Related devices
Related applications
FAQs
Does melasma have a vascular component?
Yes, histologic studies have documented increased vascularity and VEGF expression in melasma lesions. That supports the view that melasma biology can extend beyond visible epidermal pigment.
Does every melasma patient need vascular laser treatment?
No. The vascular findings are biologically important, but they do not establish that every patient should receive vascular-directed laser treatment. Treatment selection remains individualized.
Why is long-pulse 1064 nm relevant?
Long-pulse 1064 nm provides a separate photothermal pathway for appropriate vascular targets. Pro 1 Pico includes this mode alongside its 1064 nm picosecond delivery, giving providers more than one tissue interaction from the same wavelength platform.
Is there clinical evidence for a combined 1064 nm approach?
A 2025 randomized evaluator-blinded trial in Fitzpatrick III–IV patients found greater MASI improvement with combined Q-switched plus long-pulse 1064 nm Nd:YAG than with 755 nm picosecond alexandrite. The study does not prove that the benefit came specifically from vascular targeting.